ATLANTA - The federal judge in Georgia overseeing the multidistrict litigation in which direct and indirect purchasers allege that reverse settlement payments involving AndroGel violated antitrust laws ruled Sept. 28 that the brand-name drug company's underlying patent infringement lawsuit against generic drug companies was not objectively baseless (In re: Androgel Antitrust Litigation [No. II], No. 1:09-MD-2084-TWT, MDL No. 2084 [all cases], N.D. Ga.; 2012 U.S. Dist. LEXIS 140259).